ARN-75039 high

Phase 2

AArisan Therapeutics, Inc.

ARN-75039 high is one of 5 therapeutic programs targeting Lassa fever. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lassa FeverSuspended

Lassa FeverPhase 2

Suspended

Competition

Competitive Landscape

11 competitors in Lassa Fever

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

2 2

Virazole

CConrado Roberto Hoffmann Filho

Phase 2

4 3

Avigan

AAppili Therapeutics Inc.

Phase 2

2 4

ARN-75039 high

AArisan Therapeutics, Inc.

Phase 2

1 5

ARN-75039

AArisan Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lassa fever1 trial

A Phase 2 Study to Evaluate Safety, Tolerability, And Virologic Efficacy of ARN-75039 For the Treatment of Lassa Fever in West Africa

Suspended·AArisan Therapeutics, Inc.·Phase 2·NCT07419373·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARN-75039 high. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ARN-75039 high. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Arisan Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AArisan Therapeutics, Inc.

ARN-75039 high

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Lassa fever1 trial

References

Drug Info

Quick Facts

Related News